Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

This is a randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide on brain activation in areas involved in cognitive control and reward during food visualization.

Study participation will span approximately 1.5-2 months. Subjects will learn to self-administer the medication and will have a total of 8 study visits plus one screening visit. The visits will include the following tests/procedures:

Vital signs (blood pressure, temperature, heart rate, breathing rate)

Height, weight and other body measurements like waist

Blood tests

Urine pregnancy test (women only)

Electrocardiogram (EKG)

Medical history

Physical exam

Body Composition tests

Study logs to record food intake and blood sugar

functional MRI

We plan to recruit a total of 24 subjects to be treated with placebo and liraglutide. We propose to enroll 12 obese diabetic (type 2) and 12 lean diabetic (type 2) subjects. Equal numbers of men and women will be enrolled and the randomization will block for gender.